{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:12:37Z","timestamp":1791267157635,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104135"],"award-info":[{"award-number":["82104135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Heilongjiang Province Medical and Health Scientific Research Projects","award":["20220303071043"],"award-info":[{"award-number":["20220303071043"]}]},{"name":"Guangzhou Key Research Project","award":["2023B03J1343"],"award-info":[{"award-number":["2023B03J1343"]}]},{"name":"Natural Science Foundation of Guangdong province","award":["2024A1515012818"],"award-info":[{"award-number":["2024A1515012818"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["21623114"],"award-info":[{"award-number":["21623114"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glaucoma stands out as the primary cause of permanent blindness worldwide, marked by elevated intraocular pressure (IOP) and the deterioration of retinal ganglion cells (RGCs) within the optic nerve. This study aimed to investigate the therapeutic efficacy of MN-08, a novel memantine nitrate derivative, in experimental models of glaucoma. In the rat model of retinal ischemia\u2013reperfusion injury, MN-08 prevented the reduction in retinal ganglion cell complex (GCC) thickness and RGC loss. Meanwhile, MN-08 reduced the protein levels of cleaved-caspase-3, caspase-3, and Bax, while increasing the expression of Bcl-2 compared to the model group, indicating that MN-08 exerts an inhibitory effect on the apoptosis of RGCs. Furthermore, MN-08 lowered IOP in the transient ocular hypertension and glaucoma rabbit models. MN-08 significantly increased cGMP levels in human trabecular meshwork cells (HTMCs). Elevation of cGMP induced by MN-08 was eliminated by ODQ. Moreover, MN-08 attenuated the protein levels of MLCK and p-MLC-2 in HTMCs induced by endothelin-1. Additionally, MN-08 exhibited favorable distribution profiles and pharmacokinetic parameters in normal rabbit ocular tissues following topical instillation. These findings indicate that MN-08 could antagonize NMDA receptors to protect RGCs and release NO to relax TM for the treatment of glaucoma.<\/jats:p>","DOI":"10.1038\/s41598-025-06832-x","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:03:25Z","timestamp":1751576605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Huihui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangmiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"6832_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121, 2081\u20132090 (2014).","journal-title":"Ophthalmology"},{"key":"6832_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley, H. A. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262\u2013267 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"6832_CR3","first-page":"508","volume":"66","author":"E Bluwol","year":"2016","unstructured":"Bluwol, E. Glaucoma treatment. Rev. Prat. 66, 508\u2013513 (2016).","journal-title":"Rev. Prat."},{"key":"6832_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2012.09.014","volume":"13","author":"S Miglior","year":"2013","unstructured":"Miglior, S. & Bertuzzi, F. Relationship between intraocular pressure and glaucoma onset and progression. Curr. Opin. Pharmacol. 13, 32\u201335 (2013).","journal-title":"Curr. Opin. Pharmacol."},{"key":"6832_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/2040622313511286","volume":"5","author":"D Sambhara","year":"2014","unstructured":"Sambhara, D. & Aref, A. A. Glaucoma management: Relative value and place in therapy of available drug treatments. Ther. Adv. Chron. Dis. 5, 30\u201343 (2014).","journal-title":"Ther. Adv. Chron. Dis."},{"key":"6832_CR6","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1167\/iovs.14-14515","volume":"55","author":"ME Cavet","year":"2014","unstructured":"Cavet, M. E., Vittitow, J. L., Impagnatiello, F., Ongini, E. & Bastia, E. Nitric oxide (NO): An emerging target for the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 55, 5005\u20135015 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40123-017-0094-6","volume":"6","author":"J Aliancy","year":"2017","unstructured":"Aliancy, J., Stamer, W. D. & Wirostko, B. A review of nitric oxide for the treatment of glaucomatous disease. Ophthalmol Therapy 6, 221\u2013232 (2017).","journal-title":"Ophthalmol Therapy"},{"key":"6832_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/exer.1994.1199","volume":"58","author":"JS Schuman","year":"1994","unstructured":"Schuman, J. S., Erickson, K. & Nathanson, J. A. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp. Eye Res. 58, 99\u2013105 (1994).","journal-title":"Exp. Eye Res."},{"key":"6832_CR9","first-page":"2769","volume":"35","author":"C Kee","year":"1994","unstructured":"Kee, C., Kaufman, P. L. & Gabelt, B. T. Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. Invest. Ophthalmol. Vis. Sci. 35, 2769\u20132773 (1994).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0022-3565(25)11469-9","volume":"260","author":"JA Nathanson","year":"1992","unstructured":"Nathanson, J. A. Nitrovasodilators as a new class of ocular hypotensive agents. J. Pharmacol. Exp. Ther. 260, 956\u2013965 (1992).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"6832_CR11","first-page":"1711","volume":"37","author":"FF Behar-Cohen","year":"1996","unstructured":"Behar-Cohen, F. F., Goureau, O., D\u2019Hermies, F. & Courtois, Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 37, 1711\u20131715 (1996).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","volume":"99","author":"RN Weinreb","year":"2015","unstructured":"Weinreb, R. N. et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The VOYAGER study. Br. J. Ophthalmol. 99, 738\u2013745 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"6832_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","volume":"18","author":"PL Kaufman","year":"2017","unstructured":"Kaufman, P. L. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Exp. Opin. Pharmacother. 18, 433\u2013444 (2017).","journal-title":"Exp. Opin. Pharmacother."},{"key":"6832_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.exer.2011.03.001","volume":"93","author":"AH Krauss","year":"2011","unstructured":"Krauss, A. H. et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2\u03b1 agonist, in preclinical models. Exp. Eye Res. 93, 250\u2013255 (2011).","journal-title":"Exp. Eye Res."},{"key":"6832_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0002-9394(14)75421-2","volume":"121","author":"RF Brubaker","year":"1996","unstructured":"Brubaker, R. F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121, 473\u2013483 (1996).","journal-title":"Am. J. Ophthalmol."},{"key":"6832_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/OPX.0b013e31817841e5","volume":"85","author":"W Cheung","year":"2008","unstructured":"Cheung, W., Guo, L. & Cordeiro, M. F. Neuroprotection in glaucoma: drug-based approaches. Optometry Vis. Sci.: Off. Publ. Am. Acad. Optom. 85, 406\u2013416 (2008).","journal-title":"Optometry Vis. Sci.: Off. Publ. Am. Acad. Optom."},{"key":"6832_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/00003495-200767050-00006","volume":"67","author":"G Chidlow","year":"2007","unstructured":"Chidlow, G., Wood, J. P. & Casson, R. J. Pharmacological neuroprotection for glaucoma. Drugs 67, 725\u2013759 (2007).","journal-title":"Drugs"},{"key":"6832_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/ICU.0b013e32834372ec","volume":"22","author":"HV Danesh-Meyer","year":"2011","unstructured":"Danesh-Meyer, H. V. Neuroprotection in glaucoma: Recent and future directions. Curr. Opin. Ophthalmol. 22, 78\u201386 (2011).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"6832_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJM199403033300907","volume":"330","author":"SA Lipton","year":"1994","unstructured":"Lipton, S. A. & Rosenberg, P. A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613\u2013622 (1994).","journal-title":"N. Engl. J. Med."},{"key":"6832_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1017\/S0952523800005666","volume":"8","author":"R Siliprandi","year":"1992","unstructured":"Siliprandi, R. et al. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis. Neurosci 8, 567\u2013573 (1992).","journal-title":"Vis. Neurosci"},{"key":"6832_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/archopht.1996.01100130295012","volume":"114","author":"EB Dreyer","year":"1996","unstructured":"Dreyer, E. B., Zurakowski, D., Schumer, R. A., Podos, S. M. & Lipton, S. A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 114, 299\u2013305 (1996).","journal-title":"Arch. Ophthalmol."},{"issue":"Suppl 1","key":"6832_CR22","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/S0039-6257(99)00017-X","volume":"43","author":"CK Vorwerk","year":"1999","unstructured":"Vorwerk, C. K., Gorla, M. S. & Dreyer, E. B. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv. Ophthalmol. 43(Suppl 1), S142-150 (1999).","journal-title":"Surv. Ophthalmol."},{"key":"6832_CR23","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1038\/s41598-024-54075-z","volume":"14","author":"L Feng","year":"2024","unstructured":"Feng, L. et al. Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma. Sci. Rep. 14, 3834 (2024).","journal-title":"Sci. Rep."},{"key":"6832_CR24","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1016\/S0042-6989(97)00047-3","volume":"37","author":"NJ Sucher","year":"1997","unstructured":"Sucher, N. J., Lipton, S. A. & Dreyer, E. B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vis. Res. 37, 3483\u20133493 (1997).","journal-title":"Vis. Res."},{"key":"6832_CR25","first-page":"1618","volume":"37","author":"CK Vorwerk","year":"1996","unstructured":"Vorwerk, C. K. et al. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Investig. Ophthalmol. Vis. Sci. 37, 1618\u20131624 (1996).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"6832_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajo.2009.03.029","volume":"148","author":"HV Danesh-Meyer","year":"2009","unstructured":"Danesh-Meyer, H. V. & Levin, L. A. Neuroprotection: Extrapolating from neurologic diseases to the eye. Am. J. Ophthalmol. 148, 186-191.e182 (2009).","journal-title":"Am. J. Ophthalmol."},{"issue":"Suppl 1","key":"6832_CR27","first-page":"S38","volume":"48","author":"L Sa","year":"2003","unstructured":"Sa, L. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol. 48(Suppl 1), S38-46 (2003).","journal-title":"Surv. Ophthalmol."},{"key":"6832_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1167\/iovs.03-0566","volume":"45","author":"WA Hare","year":"2004","unstructured":"Hare, W. A. et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest. Ophthalmol. Vis. Sci. 45, 2625\u20132639 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/156720506777632808","volume":"3","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. The pharmacology of aminoadamantane nitrates. Curr. Alzheimer Res. 3, 201\u2013204 (2006).","journal-title":"Curr. Alzheimer Res."},{"key":"6832_CR30","doi-asserted-by":"publisher","first-page":"14781","DOI":"10.1038\/srep14781","volume":"5","author":"H Takahashi","year":"2015","unstructured":"Takahashi, H. et al. Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Sci. Rep. 5, 14781 (2015).","journal-title":"Sci. Rep."},{"key":"6832_CR31","doi-asserted-by":"publisher","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","volume":"110","author":"M Talantova","year":"2013","unstructured":"Talantova, M. et al. A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U.S.A. 110, E2518-2527 (2013).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"6832_CR32","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1111\/bph.14763","volume":"176","author":"F Luo","year":"2019","unstructured":"Luo, F. et al. The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. Br. J. Pharmacol. 176, 3318\u20133335 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"6832_CR33","doi-asserted-by":"publisher","first-page":"e13371","DOI":"10.1111\/acel.13371","volume":"20","author":"L Wu","year":"2021","unstructured":"Wu, L. et al. Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer\u2019s disease. Aging Cell 20, e13371 (2021).","journal-title":"Aging Cell"},{"key":"6832_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1039\/C6MD00509H","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases. MedChemComm 8, 135\u2013147 (2017).","journal-title":"MedChemComm"},{"key":"6832_CR35","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1161\/HYPERTENSIONAHA.120.15994","volume":"77","author":"F Luo","year":"2021","unstructured":"Luo, F. et al. Dual-functional MN-08 attenuated pulmonary arterial hypertension through vasodilation and inhibition of pulmonary arterial remodeling. Hypertension (Dallas, Tex: 1979) 77, 1787\u20131798 (2021).","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"6832_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.intimp.2018.11.010","volume":"66","author":"J Jiang","year":"2019","unstructured":"Jiang, J. et al. The novel N-methyl-d-aspartate receptor antagonist MN-08 ameliorates lipopolysaccharide-induced acute lung injury in mice. Int. Immunopharmacol. 66, 109\u2013118 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"6832_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/ijms20040981","volume":"20","author":"C Lanzi","year":"2019","unstructured":"Lanzi, C. et al. Role of histamine H3 receptor antagonists on intraocular pressure reduction in rabbit models of transient ocular hypertension and glaucoma. Int. J. Mol. Sci. 20, 981 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"6832_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/14756366.2011.597749","volume":"27","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi, F. et al. A new approach to antiglaucoma drugs: Carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J. Enzyme Inhib. Med. Chem. 27, 138\u2013147 (2012).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"6832_CR39","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of glaucoma: A review. JAMA 311, 1901\u20131911 (2014).","journal-title":"JAMA"},{"key":"6832_CR40","doi-asserted-by":"publisher","first-page":"114781","DOI":"10.1016\/j.addr.2023.114781","volume":"196","author":"A Hakim","year":"2023","unstructured":"Hakim, A., Guido, B., Narsineni, L., Chen, D. W. & Foldvari, M. Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems. Adv. Drug Deliv. Rev. 196, 114781 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"6832_CR41","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/ph17101261","volume":"17","author":"LH Wang","year":"2024","unstructured":"Wang, L. H., Huang, C. H. & Lin, I. C. Advances in neuroprotection in glaucoma: Pharmacological strategies and emerging technologies. Pharmaceuticals (Basel) 17, 1261 (2024).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 3","key":"6832_CR42","doi-asserted-by":"publisher","first-page":"S284","DOI":"10.1016\/S0039-6257(01)00200-4","volume":"45","author":"W Hare","year":"2001","unstructured":"Hare, W. et al. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol. 45(Suppl 3), S284-289 (2001).","journal-title":"Surv. Ophthalmol."},{"key":"6832_CR43","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1167\/iovs.03-0567","volume":"45","author":"WA Hare","year":"2004","unstructured":"Hare, W. A. et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest. Ophthalmol. Vis. Sci. 45, 2640\u20132651 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/00061198-200212000-00003","volume":"11","author":"E WoldeMussie","year":"2002","unstructured":"WoldeMussie, E., Yoles, E., Schwartz, M., Ruiz, G. & Wheeler, L. A. Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma 11, 474\u2013480 (2002).","journal-title":"J. Glaucoma"},{"key":"6832_CR45","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","volume":"125","author":"RN Weinreb","year":"2018","unstructured":"Weinreb, R. N. et al. Oral memantine for the treatment of glaucoma: Design and Results of 2 randomized, placebo-controlled, phase 3 studies. Ophthalmology 125, 1874\u20131885 (2018).","journal-title":"Ophthalmology"},{"issue":"2","key":"6832_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","volume":"31","author":"M Almasieh","year":"2012","unstructured":"Almasieh, M., Wilson, A. M., Morquette, B., Vargas, J. L. C. & Di Polo, A. The molecular basis of retinal ganglion cell death in glaucoma. Progress Retin. Eye Res. 31(2), 152\u2013181 (2012).","journal-title":"Progress Retin. Eye Res."},{"issue":"18","key":"6832_CR47","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of glaucoma: A review. JAMA 311(18), 1901\u20131911 (2014).","journal-title":"JAMA"},{"key":"6832_CR48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.4103\/1673-5374.184448","volume":"11","author":"M Foldvari","year":"2016","unstructured":"Foldvari, M. & Chen, D. W. The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: A case for gene therapy. Neural Regen. Res. 11, 875\u2013877 (2016).","journal-title":"Neural Regen. Res."},{"key":"6832_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.niox.2018.04.010","volume":"77","author":"LK Wareham","year":"2018","unstructured":"Wareham, L. K., Buys, E. S. & Sappington, R. M. The nitric oxide-guanylate cyclase pathway and glaucoma. Nitric. Oxide Biol. Chem. 77, 75\u201387 (2018).","journal-title":"Nitric. Oxide Biol. Chem."},{"key":"6832_CR50","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.1167\/iovs.09-5072","volume":"51","author":"DZ Ellis","year":"2010","unstructured":"Ellis, D. Z., Sharif, N. A. & Dismuke, W. M. Endogenous regulation of human Schlemm\u2019s canal cell volume by nitric oxide signaling. Invest. Ophthalmol. Vis. Sci. 51, 5817\u20135824 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"6832_CR51","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.mam.2023.101223","volume":"94","author":"E Ekici","year":"2023","unstructured":"Ekici, E. & Moghimi, S. Advances in understanding glaucoma pathogenesis: A multifaceted molecular approach for clinician scientists. Mol. Aspect. Med. 94, 101223 (2023).","journal-title":"Mol. Aspect. Med."},{"key":"6832_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/ICU.0b013e3280895aea","volume":"18","author":"N Gupta","year":"2007","unstructured":"Gupta, N. & Y\u00fccel, Y. H. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 18, 110\u2013114 (2007).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"6832_CR53","first-page":"793931","volume":"2010","author":"DA Valenti","year":"2011","unstructured":"Valenti, D. A. Alzheimer\u2019s disease and glaucoma: Imaging the biomarkers of neurodegenerative disease. Int. j. Alzheimer\u2019s Dis. 2010, 793931 (2011).","journal-title":"Int. j. Alzheimer\u2019s Dis."},{"key":"6832_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neuroscience.2010.10.071","volume":"172","author":"SK Brandt","year":"2011","unstructured":"Brandt, S. K., Weatherly, M. E., Ware, L., Linn, D. M. & Linn, C. L. Calcium preconditioning triggers neuroprotection in retinal ganglion cells. Neuroscience 172, 387\u2013397 (2011).","journal-title":"Neuroscience"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06832-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:01:30Z","timestamp":1751580090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06832-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23822"}}